The combination therapy of melflufen (melphalan flufenamide) and dexamethasone continues to be safe and to elicit deep and durable responses in hard-to-treat patients with relapsed or refractory multiple myeloma, top-line data from a Phase 2 clinical trial shows. The findings will support Oncopeptides‘ submission of a new drug application requesting accelerated approval of melflufen for treating relapsed or refractory myeloma patients in the U.S., which remains on track for later this year, despite the COVID-19 pandemic. Trial…
You must be logged in to read/download the full post.
The post Oncopeptides Reports Positive Results from HORIZON Trial of Melflufen Combo appeared first on BioNewsFeeds.